Pasar al contenido principal

LA RUTA RAS/MAPK COMO NUEVA DIANA TERAPETICA PARA EL NEUROBLASTOMA RECURRENTE

PID2022-136409OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE SEVILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Sos1 ablation alters focal adhesion dynamics and increases Mmp2/9-dependent gelatinase activity in primary mouse embryonic fibroblasts

  • Liceras-Boillos, Pilar
  • García-Navas, Rósula
  • Llorente-González, Clara
  • Lorenzo-Martín, L. Francisco
  • Luna Ramírez, Luis
  • Fuentes Mateos, Rocío
  • Calzada, Nuria
  • Vega, Francisco M.
  • Holt, Mark R.
  • Ridley, Anne J.
  • Bustelo, Xosé R.
  • Vicente-Manzanares, Miguel
  • Santos de Dios, Eugenio
  • Baltanás, Fernando C.
[Background] Sos1 and Sos2 are guanine-nucleotide exchange factors for Ras and Rac small GTPases, which are involved in a wide range of cellular responses including proliferation and migration. We have previously shown that Sos1 and Sos2 have different effects on cell migration, but the underlying mechanisms are not clear., [Methods] Using a 4-hydroxytamoxifen-inducible conditional Sos1KO mutation, here we evaluated the functional specificity or redundancy of Sos1 and Sos2 regarding the control of cell migration and dynamics of focal adhesions (FAs) in primary mouse embryonic fibroblasts (MEFs)., [Results] Functional analysis of the transcriptome of primary Sos1/2WT, Sos1KO, Sos2KO and Sos1/2DKO-MEFs revealed a specific, dominant role of Sos1 over Sos2 in transcriptional regulation. Sos1KO MEFs had an increased number and stability of focal adhesions (FAs) and curbed protrusion and spreading. Conversely, Sos2KO MEFs displayed unstable FAs with increased protrusion. Interestingly, Sos1, but not Sos2, ablation reduced the levels of GTP-bound Rac at the leading edge. In 3D, however, only Sos1/2KO MEFs showed increased invasion and matrix degradative capacity, which correlated with increased expression of the Mmp2 and Mmp9 gelatinases. Moreover, increased matrix degradation in Sos1/2KO MEFs was abrogated by treatment with Mmp2/9 inhibitors., [Conclusions] Our data demonstrate that Sos1 and Sos2 have different functions in FAs distribution and dynamics in 2D whereas in 3D they act together to regulate invasion and unveil a previously undescribed mechanistic connection between Sos1/2 and the regulation of Mmp2/9 expression in primary MEFs., This work was funded by grants ISCIII-MCUI (FIS PI19/00934), JCyL (SA264P18-UIC 076), Areces Foundation (CIVP19A5942) and ISCIII-CIBERONC (group CB16/12/00352) to E.S; Solórzano-Barruso Foundation (FS/32-2020), Ministerio de Ciencia e Innovación (MICIU/AEI/https://doi.org/10.13039/501100011033/, as part of I + D + i Project “PID2022-136409OB-I00” and MICIU/AEI/https://doi.org/10.13039/501100011033/ and NextGenerationEU/PRTR, as part of I + D + i Project “CNS2022-135292), Eugenio Rodriguez Pascual Foundation and Asociación Inés de Pablo Llorens-GETTHI to F.C.B; Federación Española de Enfermedades Raras (AI-2023-015) to F.M.V; Ministerio de Ciencia e Innovación (PID2020-116232RB-I00) and ECRIN-M3 from AECC/AIRC/CRUK to M.V-M; Cancer Research UK (C6620/A15961) to A.J.R. The X.R.B.’s project leading to these results has received funding from the AECC (GC16173472GARC), the Castilla-León government (CSI018P23), grants funded by MCIN/AEI/https://doi.org/10.13039/501100011033/ plus the European Research Development Fund «A way of making Europe» of the European Union (PID2021-122666OB-I00, PDC2022-133027-I00, PLEC2022-009217), «la Caixa» Banking Foundation (HR20-00164), and the «Escalera de Excelencia» of the Education Ministry of the Castilla y León autonomous government plus the European Research Development Fund (CLU-2023-2-01). This research was co-financed by FEDER funds. These CIC groups are supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia of Castilla y León autonomous government (CLC-2017-01) and AECC Excellence program Stop RAS Cancers (EPAEC222641CICS)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRASG12D inhibitor in KRAS LUAD

  • Baltanás, Fernando C.
  • Kramer Drauberg, Maximilian
  • García-Navas, Rósula
  • Patrucco, Enrico
  • Petrini, Ettore
  • Arnhof, Heribert
  • Olarte-San Juan, Andrea
  • Rodríguez-Ramos, Pablo
  • Borrajo, Javier
  • Calzada, Nuria
  • Castellano, Esther
  • Mair, Barbara
  • Kostyrko, Kaja
  • Hofmann, Marco H.
  • Ambrogio, Chiara
  • Santos de Dios, Eugenio
We evaluated the in vivo therapeutic efficacy and tolerability of BI-3406-mediated pharmacological inhibition of SOS1 in comparison to genetic ablation of this universal Ras-GEF in various KRAS-dependent experimental tumor settings. Contrary to the rapid lethality caused by SOS1 genetic ablation in SOS2KO mice, SOS1 pharmacological inhibition by its specific inhibitor BI-3406 did not significantly affect animal weight/viability nor cause noteworthy systemic toxicity. Allograft assays using different KRASmut cell lines showed that treatment with BI-3406 impaired RAS activation and RAS downstream signaling and decreased tumor burden and disease progression as a result of both tumor-intrinsic and -extrinsic therapeutic effects of the drug. Consistent with prior genetic evidence and the KRASmut allografts assays in immunocompromised mice, our analyses using an in vivo model of KRASG12D-driven lung adenocarcinoma (LUAD) in immunocompetent mice showed that single, systemic BI-3406 treatment impaired tumor growth and downmodulated protumorigenic components of the tumor microenvironment comparably to SOS1 genetic ablation or to treatment with the specific KRASG12D inhibitor MRTX1133. Furthermore, markedly stronger, synergistic antitumor effects were observed upon concomitant treatment with BI-3406 and MRTX1133 in the same in vivo LUAD mouse model. Our data confirm SOS1 as an actionable therapy target in RAS-dependent cancers and suggest that BI-3406 treatment may yield clinical benefit both as monotherapy or as a potential combination partner for multiple RAS-targeting strategies., Instituto de Salud Carlos III-Ministerio de Ciencia e Innovación grant FIS PI19/00934 (E.S.) Junta de Castilla y León grant SA264P18-UIC 076 (E.S.) Fundación Ramón Areces grant CIVP19A5942 (E.S.) Instituto de Salud Carlos III -CIBERONC grant CB16/12/00352 (E.S.) Asociación Española Contra el Cancer Excellence program STOP RAS CANCERS grant EPAEC222641CICS (E.S.) MICIU/AEI/10.13039/501100011033/ grant PID2022-136409OB-I00 (F.C.B.) MICIU/AEI/10.13039/501100011033/ and European Union NextGenerationEU/PRTR grant CNS2022-135292 (F.C.B.) Fundación Solorzano-Barruso grant FS/32-2020 (F.C.B.) Fundación Eugenio Rodríguez Pascual (F.C.B.) Asociación Inés de Pablo Llorens-Grupo GETTHI (F.C.B.) Ministerio de Ciencia e Innovación grant RTI2018-099161-A-I00 (E.C.) The Giovanni Armenise–Harvard Foundation (C.A.) The European Research Council under the European Union’s Horizon 2020 research and innovation programme grant 101001288 (C.A.) MIUR FARE grant R207ENY9KZ (C.A.) AIRC under IG 2021 - ID. 25737 (C.A.) This research was cofinanced by FEDER funds. These CIC groups are supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia of Castilla y León autonomous government (CLC-2017-01). M.K.-D. was supported by Fondazione Umberto Veronesi. C.A. is supported by the Zanon di Valgiurata family through Justus s.s. The research project was selected and funded for 2 y by Boehringer Ingelheim in a Molecule for Collaboration (M4C) call submitted to the opn.me platform (www.opnme.com) We thank Astrid Jeschko for her contribution performing the Pharmacokinetic studies, Peer reviewed